论文部分内容阅读
目的探讨晚期胰腺癌体内放射治疗延长患者生存期、改善生活质量的有效性及可行性。方法对我院2002年9月-2007年9月间收治的60例晚期胰腺癌患者永久植入放射量为0.3～1.0mCi的125I粒子,术后随诊观察生存期、疼痛缓解及并发症发生率。结果所有病例得到随诊,患者植入术后中位生存期平均189d。其中39例术后CT及MRI随诊肿瘤明显缩小;9例患者术后生存超过1年,占15%;3例患者经125I治疗后1个月成功行胰十二指肠切除术。所有患者无明显骨髓抑制。结论经125I治疗的患者中位生存期明显延长。证明CT导向下125I粒子植入治疗晚期胰腺癌有效可行,其优越性为靶器官准确且正常组织损伤小、方法简便经济。
Objective To investigate the efficacy and feasibility of in vivo radiotherapy for advanced pancreatic cancer to prolong survival and improve quality of life. Methods Sixty-two patients with advanced pancreatic cancer who were treated in our hospital from September 2002 to September 2007 were permanently implanted with 125I particles with a dose of 0.3-1.0mCi. The survival time, pain relief and complications were observed after operation rate. Results All the cases were followed up. The median survival time after implantation was 189 days. Among them, the tumor size of 39 cases were significantly reduced after CT and MRI follow-up. Nine patients survived more than one year after operation, accounting for 15%. Three patients underwent successful pancreatoduodenectomy 1 month after 125I treatment. All patients had no significant myelosuppression. Conclusions The median survival of patients treated with 125I was significantly longer. Proved CT-guided 125I seed implantation in the treatment of advanced pancreatic cancer is feasible and effective, the advantages of the target organ is accurate and normal tissue damage is small, the method is simple and economical.